Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mabpharm Limited ( (HK:2181) ) has shared an update.
Mabpharm Limited announced that all proposed resolutions at its Annual General Meeting held on June 18, 2025, were passed unanimously by shareholders. These resolutions included the re-election of directors, the re-appointment of auditors, and the granting of mandates to the board for share repurchase and issuance. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational stability.
More about Mabpharm Limited
Mabpharm Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company is listed on the Hong Kong Stock Exchange and focuses on developing and commercializing innovative drugs, particularly in the field of oncology and autoimmune diseases.
Average Trading Volume: 617,320
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.04B
Learn more about 2181 stock on TipRanks’ Stock Analysis page.